Cholangiocarcinoma is a group of malignancies with poor prognosis. Treatments for the management of advanced-stage cholangiocarcinoma are limited, and the 5-year survival rate is estimated to be approximately 5–15%, considering all tumor stages. There is a significant unmet need for effective new treatment approaches. The present review is provided with the aim of summarizing the current evidence and future perspectives concerning new therapeutic strategies for cholangiocarcinoma. The role of targeted therapies and immunotherapies is currently investigational in cholangiocarcinoma. These therapeutic options might improve survival outcomes, as shown by the promising results of several clinical trials illustrated in the present review. The co-presence of driver mutations and markers of susceptibility to immunotherapy may lead to rational combination strategies and clinical trial development. A better understanding of immunologically based therapeutic weapons is needed, which will lead to a form of a precision medicine strategy capable of alleviating the clinical aggressiveness and to improve the prognosis of cholangiocarcinoma.

Emerging therapies for advanced cholangiocarcinoma. An updated literature review / Vignone, A.; Biancaniello, F.; Casadio, M.; Pesci, L.; Cardinale, V.; Ridola, L.; Alvaro, D.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:21(2021), pp. 1-11. [10.3390/jcm10214901]

Emerging therapies for advanced cholangiocarcinoma. An updated literature review

Vignone A.
;
Biancaniello F.
;
Casadio M.;Pesci L.;Cardinale V.;Ridola L.;Alvaro D.
2021

Abstract

Cholangiocarcinoma is a group of malignancies with poor prognosis. Treatments for the management of advanced-stage cholangiocarcinoma are limited, and the 5-year survival rate is estimated to be approximately 5–15%, considering all tumor stages. There is a significant unmet need for effective new treatment approaches. The present review is provided with the aim of summarizing the current evidence and future perspectives concerning new therapeutic strategies for cholangiocarcinoma. The role of targeted therapies and immunotherapies is currently investigational in cholangiocarcinoma. These therapeutic options might improve survival outcomes, as shown by the promising results of several clinical trials illustrated in the present review. The co-presence of driver mutations and markers of susceptibility to immunotherapy may lead to rational combination strategies and clinical trial development. A better understanding of immunologically based therapeutic weapons is needed, which will lead to a form of a precision medicine strategy capable of alleviating the clinical aggressiveness and to improve the prognosis of cholangiocarcinoma.
2021
cholangiocarcinoma; immunotherapy; targeted therapy
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Emerging therapies for advanced cholangiocarcinoma. An updated literature review / Vignone, A.; Biancaniello, F.; Casadio, M.; Pesci, L.; Cardinale, V.; Ridola, L.; Alvaro, D.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:21(2021), pp. 1-11. [10.3390/jcm10214901]
File allegati a questo prodotto
File Dimensione Formato  
Vignone_Emerging-therapies_2021.pdf

accesso aperto

Note: https://www.mdpi.com/2077-0383/10/21/4901
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 240.41 kB
Formato Adobe PDF
240.41 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1595285
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 5
social impact